Zoltan Antal, M.D.
Recognizing the inherent difficulties in dealing with challenging and often lifelong illnesses in pediatric endocrinology,I strive to get to know my patients and their families personally. Emphasizing family involvement while simultaneously promotinga child’s individuality, growth and independence often results in excellent outcomes. I believe honesty and open andclear communication are the most important components of a healthy relationship between a patient and their doctor.
Dr. Zoltan Antal is the Director of the Pediatric Diabetes Program in the Division of Pediatric Endocrinology, and an Assistant Professor of Pediatrics at Weill Cornell Medical College. He is also an Assistant Attending Pediatrician at NewYork-Presbyterian Hospital. He is board certified in Pediatrics and Pediatric Endocrinology.
Dr. Antal received a B.S. in Biology from Stony Brook University in Stony Brook, New York and completed his medical degree (M.D.) from St. George’s University School of Medicine in Grenada, West Indies in combination with clinical rotations at Jamaica Hospital in Queens, New York City. He went on to complete his Residency in Pediatrics in Brooklyn, New York at SUNY Downstate Medical Center and Kings County Hospital, where he later served as chief resident. After residency, he remained in New York City and completed a fellowship in Pediatric Endocrinology at the Children’s Hospital at Montefiore in the Bronx.
During his fellowship, Dr. Antal also conducted research at the Albert Einstein College of Medicine in the immunology of diabetes. Specifically, he isolated islet cells from pancreata of diabetic mice and studied the targets of the islet infiltrating T cells. In addition, he was also in charge of the translational component of the research, which entailed examining the peripheral blood of children newly diagnosed with type 1 diabetes, searching for reactivity to the human counterparts of the murine T cell targets.
Finally, Dr. Antal and his colleagues analyzed the HLA supertypes of a subset of diabetic children, publishing the findings in the Annals of the New York Academy of Sciences in 2008.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA [HMO]
- AETNA [PPO]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [HMO]
- Antal Z, Baker JC, Smith C, Jarchum I, Babad J, Mukherjee G, Yang Y, Sidney J, Sette A, Santamaria P, Dilorenzo TP. Beyond HLA-A*0201: New HLA-Transgenic Nonobese Diabetic Mouse Models of Type 1 Diabetes Identify the Insulin C-Peptide as a Rich Source of CD8+ T Cell Epitopes. J Immunol. 2012 Apr 25. [Epub ahead of print] PubMed PMID: 22539795.
- Zhou P, Chaudhari RS, Antal Z. Gender differences in cardiovascular risks of
obese adolescents in the Bronx. J Clin Res Pediatr Endocrinol. 2010;2(2):67-71.
Epub 2010 May 3. PubMed PMID: 21274341; PubMed Central PMCID: PMC3005672.
- Reynholds C, Antal Z. Analysis of the NovoPen® Echo for the delivery of
insulin: a comparison of usability, functionality, and preference among pediatric
subjects, their parents, and health care professionals. J Diabetes Sci Technol.
2010 Nov 1;4(6):1476-8. PubMed PMID: 21129344; PubMed Central PMCID: PMC3005059.
- Antal Z, Zhou P. Addison disease. Pediatr Rev. 2009 Dec;30(12):491-3. PubMed
- Antal Z, Zhou P. Congenital adrenal hyperplasia: diagnosis, evaluation, and
management. Pediatr Rev. 2009 Jul;30(7):e49-57. Review. PubMed PMID: 19570920.
- Antal Z, Zhou P. In Brief – Addison's Disease. Pediatrics in Review. Accepted for publication 2009.
- Antal Z, Karlsson H, Saenger P. Effectiveness of late Growth Hormone Therapy (>12 years CA) in Turner Syndrome. Abstract, LWPES 2009
- Antal Z, Lee TA, Babila S, Markowitz M. Epidermal Nevus Syndrome and Hypophosphatemic Rickets: Secretion of a Phosphaturic Agent? Abstract, Endocrine Society 2009
Honors and Awards
Leo M. Davidoff Society inductee for outstanding achievement in the teaching of medial students, May 2009
Pediatric Research Day Oral Presentation Award, April 2009
Fellows' resident teaching award, June 2007
Doctor's Day award, March 2006
Pulmonary Research Award, May 2005
- Pediatric Endocrinology
- Pediatric Diabetes
- Thyroid Disease
- Pituitary Disease
- Disorder of Adrenal Gland
- Growth Disorder
- Pubertal Disorders
- Developmental Disorder
- Short Stature
- Thyroid Disorder
- Congenital Adrenal Hyperplasia
- Ambiguous Genitalia
- Pediatric Endocrinology
- B.S., State University of New York at Stony Brook, 1998
- M.D., St. George's University School of Medicine (Grenada), 2002